Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662610 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
A Phase 1 study, sponsored by NicOx.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT00662610 is a Phase 1 study that has completed, run by NicOx. The registered enrollment target is 120 participants.
The verdict
NCT00662610, a Phase 1 study, has completed, sponsored by NicOx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
Interventions
- DRUG naproxcinod 375 mg -750 mg -1125 mg bid
- DRUG naproxen 250 mg - 500mg -750 mg bid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662610
The ClinicalTrials.gov registry entry for NCT00662610 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NicOx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which naproxcinod 375 mg -750 mg -1125 mg bid is the first listed.
NCT00662610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662610 about?
NCT00662610 is a clinical study titled "A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure". To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
What is the current status of trial NCT00662610?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2008-03. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00662610?
The interventions under investigation include: naproxcinod 375 mg -750 mg -1125 mg bid (DRUG), naproxen 250 mg - 500mg -750 mg bid (DRUG).
Who is sponsoring clinical trial NCT00662610?
This trial is sponsored by NicOx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.